Basic treatment of rheumatoid arthritis: new approachesBasic
treatment of rheumatoid arthritis: new approaches.
Kovalenko V.N., Golovkov Y. Z. Basic treatment of rheumatoid
arthritis: new approaches. Revmatology in Europe 1997, Vol. 26,
Suppl. 2, Abst. 446.
Ukrainian Centre of
Rheumatology, Kiev, Ukraine. 50th Anniversary, EULAR 97, 10th
Symposium - Vienna, Austria - November 19-22, 1997
The both groups were
comparable by the age, severity of their disease, and accompanying
diseases.
The WOBENZYM was given
during 1 year, at the dose of 15 tablets a day. The treatment
efficacy was estimated by the data of clinical, laboratory and
instrumental findings, every month. The intensity of pain syndrome
reduced in pts of BG from 6,85 ± 0,28 to 2,8 ± 0,19 /points/
(p<0,01), while in pts of CG from 7,04 ± 0,26 to 3,87 ± 0,24
/points/ (p<0,01), but this reduction was more pronounced in pts of
BG (p<0,01).
Pain reduction by 50 % was
observed in 85 % of BG but only in 39,1 % of CG pts. (p<0,05).
Patient self-evaluation of treatment efficacy coincided with
physician evalutation in 87,5 % of BG pts, while in CG – 68 %
(p<0,05). There was observed positive dynamics of Stanford form
indices: from 31,2 ± 3,5 (units) to 22,1 ± 3,4 in the BG (p<0,05),
while in the CG changes were insignificant. Also we have observed
increase of hand strength in BG and CG by 4,52 ± 0,86 kg and 2,27 ±
0,51 kg accordingly (p<0,05). We have not observed adverse reactions
in BG, while in 20 % of CG pts. (p<0,01). By infrared thermography
data resumption of inflammatory process, or its essential reduction
was stated, ESR also decreased (p<0,05).
As evidenced by the data presented, WOBENZYM® application in treatment of RA pts permits to effective curative results at absence of adverse reactions.